Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells

Bibliography

• Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 2000;96:4307-12
   PubMed Web of Science ®Google Scholar
• Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998;10:457-70
   PubMed Web of Science ®Google Scholar
• Tarkowski M. Expression and a role of CD30 in regulation of T-cell activity. Curr Opin Hematol 2003;10:267-71
   PubMed Web of Science ®Google Scholar
• Hecht TT, Longo DL, Cossman J, Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells. J Immunol 1985;134:4231-6
   PubMed Web of Science ®Google Scholar
• Segal GH, Kjeldsberg CR, Smith GP, CD30 antigen expression in florid immunoblastic proliferations. A clinicopathologic study of 14 cases. Am J Clin Pathol 1994;102:292-8
   PubMed Web of Science ®Google Scholar
• Younes A, Carbone A. CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders. Int J Biol Markers 1999;14:135-43
   PubMed Web of Science ®Google Scholar
• Pizzolo G, Vinanten F, Chilosi M, CD30 antigen and cellular biology of Reed-Sternberg cells. Blood 1994;84:3983-4
   PubMed Web of Science ®Google Scholar
• Ansell SM, Armitage JO. Management of Hodgkin lymphoma. Mayo Clin Proc 2006;81:419-26
   PubMed Web of Science ®Google Scholar
• Josting A, Katay I, Rueffer U, Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem-cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). Ann Oncol 1998;9:289-95
   PubMed Web of Science ®Google Scholar
• Linch D, Winfield D, Goldstone A, Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051-4
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065-71
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Nimer SD, Zelenetz AD, Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003;32:673-9
   PubMed Web of Science ®Google Scholar
• Devizzi L, Santoro A, Bonfante V, Vinorelbine: a new promising drug in Hodgkin's disease. Leuk Lymphoma 1996;22:409-14
   PubMed Web of Science ®Google Scholar
• Santoro A, Bredenfield H, Devizzi L, Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000;18:2615-19
   PubMed Web of Science ®Google Scholar
• Robinson SP, Goldstone AH, Mackinnon S, Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310-16
   PubMed Web of Science ®Google Scholar
• Stein H, Foss HD, Durkop H, CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681-95
   PubMed Web of Science ®Google Scholar
• Medeiros LJ, Elenitoba-Johnson KS. Anaplastic large cell lymphoma. Am J Clin Pathol 2007;127:707-22
   PubMed Web of Science ®Google Scholar
• Savage KJ, Harris NL, Vose JM, ALK– anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-504
   PubMed Web of Science ®Google Scholar
• ten Berge RL, Oudejans JJ, Ossenkoppele GJ, ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects – a review. J Pathol 2003;200:4-15
   PubMed Web of Science ®Google Scholar
• Fanin R, Ruiz de Elvira MC, Sperotto A, Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999;23:437-42
   PubMed Web of Science ®Google Scholar
• Deconinck E, Lamy T, Foussard C, Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol 2000;109:736-42
   PubMed Web of Science ®Google Scholar
• Wahl AF, Klussman K, Thompson JD, The anti-CD30 mAb SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002;62:3736-42
   PubMed Web of Science ®Google Scholar
• Duvic M, Reddy SA, Pinter-Brown L, A Phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 2009;15:6217-24
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Leonard JP, Younes A, A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146:171-9
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65
   PubMed Web of Science ®Google Scholar
• Doronina SO, Bovee TD, Meyer DW, Novel peptide linkers for highly potent antibody–auristatin conjugate. Bioconjug Chem 2008;19:1960-3
   PubMed Web of Science ®Google Scholar
• Okeley NM, Miyamoto JB, Zhang X, Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010;16:888-97
   PubMed Web of Science ®Google Scholar
• Oflazoglu E, Kissler KM, Sievers EL, Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 2008;142:69-73
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-21
   PubMed Web of Science ®Google Scholar
• Fanale M, Bartlett NL, Forero-Torres A, The antibody-drug conjugate brentuximab vedotin (SGN-35) induced multiple objective responses in patients with relapsed or refractory CD30-positive lymphomas in a phase 1 weekly dosing study [abstract #2731]. American Society of Hematology Annual Meeting 2009
   Google Scholar
• Chen R, Gopal AK, Smith SE, Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory hodgkin lymphoma [abstract #283]. American Society of Hematology Annual Meeting 2010
   Google Scholar
• Shustov AR, Advani R, Brice P, Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma [abstract #961]. American Society of Hematology Annual Meeting 2010
   Google Scholar